Virginia Dalton

2.5k total citations · 1 hit paper
17 papers, 1.7k citations indexed

About

Virginia Dalton is a scholar working on Public Health, Environmental and Occupational Health, Pediatrics, Perinatology and Child Health and Hematology. According to data from OpenAlex, Virginia Dalton has authored 17 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Public Health, Environmental and Occupational Health, 6 papers in Pediatrics, Perinatology and Child Health and 5 papers in Hematology. Recurrent topics in Virginia Dalton's work include Acute Lymphoblastic Leukemia research (10 papers), Childhood Cancer Survivors' Quality of Life (6 papers) and Chemotherapy-induced cardiotoxicity and mitigation (4 papers). Virginia Dalton is often cited by papers focused on Acute Lymphoblastic Leukemia research (10 papers), Childhood Cancer Survivors' Quality of Life (6 papers) and Chemotherapy-induced cardiotoxicity and mitigation (4 papers). Virginia Dalton collaborates with scholars based in United States, Canada and Puerto Rico. Virginia Dalton's co-authors include Stephen E. Sallan, Steven E. Lipshultz, Stuart R. Lipsitz, Richard D. Gelber, Steven D. Colan, Suzanne M. Mone, Lewis B. Silverman, Nader Rifai, David B. Sacks and Michael E. Ottlinger and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of Clinical Oncology.

In The Last Decade

Virginia Dalton

17 papers receiving 1.7k citations

Hit Papers

Chronic Progressive Cardiac Dysfunction Years After Doxor... 2005 2026 2012 2019 2005 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Chronic Progressive Cardiac Dysfunction Years After Doxorubicin Therapy for Childhood Acute Lymphoblastic Leukemia
    2005 512 citations Steven E. Lipshultz, Stuart R. Lipsitz et al. Journal of Clinical Oncology profile →

Peers

Virginia Dalton
Yvan Samson Canada
Donna E. Levy United States
Elly Barry United States
Kasey J. Leger United States
Jos P.M. Bökkerink Netherlands
Lucius F. Sinks United States
Demetrius Traggis United States
Claudine Schmitt France
Dipti Gupta United States
Furqan Shaikh Canada
Yvan Samson Canada
Virginia Dalton
Citations per year, relative to Virginia Dalton Virginia Dalton (= 1×) peers Yvan Samson

Countries citing papers authored by Virginia Dalton

Since Specialization
Citations

This map shows the geographic impact of Virginia Dalton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Virginia Dalton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Virginia Dalton more than expected).

Fields of papers citing papers by Virginia Dalton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Virginia Dalton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Virginia Dalton. The network helps show where Virginia Dalton may publish in the future.

Co-authorship network of co-authors of Virginia Dalton

This figure shows the co-authorship network connecting the top 25 collaborators of Virginia Dalton. A scholar is included among the top collaborators of Virginia Dalton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Virginia Dalton. Virginia Dalton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Nadeem, Omar, Paul G. Richardson, Jacob P. Laubach, et al.. (2020). Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma. Blood. 136(Supplement 1). 25–26. 1 indexed citations
2.
Brown, Jennifer R., Bradley T. Messmer, Lillian Werner, et al.. (2010). A Phase I Study of Escalated Dose Subcutaneous Alemtuzumab Given Weekly with Rituximab In Relapsed CLL/SLL.. Blood. 116(21). 1381–1381. 2 indexed citations
3.
Friedberg, Jonathan W., Jennifer L. Kelly, Donna Neuberg, et al.. (2009). Phase II study of a TLR‐9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. British Journal of Haematology. 146(3). 282–291. 71 indexed citations
4.
Brown, Jennifer R., Jeremy S. Abramson, Ephraim P. Hochberg, et al.. (2009). A Phase I Study of Lenalidomide in Combination with Fludarabine-Rituximab in Previously Untreated CLL/SLL.. Blood. 114(22). 3426–3426. 4 indexed citations
5.
Zhou, Jianbiao, Meredith A. Goldwasser, Aihong Li, et al.. (2007). Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood. 110(5). 1607–1611. 86 indexed citations
6.
Lipshultz, Steven E., Stuart R. Lipsitz, Rebecca E. Scully, et al.. (2007). Abstract 2550: N-terminal Pro-brain Natriuretic Peptide-defined Cardiomyopathy in Doxorubicin-treated Children with Acute Lymphoblastic Leukemia. Circulation. 116(suppl_16). 1 indexed citations
7.
Friedberg, Jonathan W., Jennifer L. Kelly, Jeffrey L. Kutok, et al.. (2006). Combination Immunotherapy with a CpG Oligonucleotide and Rituximab (R) Augments the Immunological Response and Favorably Alters the Malignant Microenvironment of Follicular Lymphoma (FL).. Blood. 108(11). 2713–2713. 2 indexed citations
8.
Li, Aihong, Meredith A. Goldwasser, Jianbiao Zhou, et al.. (2005). Distinctive IGH gene segment usage and minimal residual disease detection in infant acute lymphoblastic leukaemias. British Journal of Haematology. 131(2). 185–192. 8 indexed citations
9.
Lipshultz, Steven E., Stuart R. Lipsitz, Stephen E. Sallan, et al.. (2005). Chronic Progressive Cardiac Dysfunction Years After Doxorubicin Therapy for Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 23(12). 2629–2636. 512 indexed citations breakdown →
10.
11.
Lipshultz, Steven E., Nader Rifai, Virginia Dalton, et al.. (2004). The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia. New England Journal of Medicine. 351(2). 145–153. 422 indexed citations
12.
13.
14.
Leclerc, Jean Marie, Amy L. Billett, Richard D. Gelber, et al.. (2002). Treatment of Childhood Acute Lymphoblastic Leukemia: Results of Dana-Farber ALL Consortium Protocol 87-01. Journal of Clinical Oncology. 20(1). 237–246. 20 indexed citations
15.
Dalton, Virginia, et al.. (2001). Bony Morbidity in Children Treated for Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 19(12). 3066–3072. 174 indexed citations
16.
Lipshultz, Steven E., Nader Rifai, Stephen E. Sallan, et al.. (1997). Predictive Value of Cardiac Troponin T in Pediatric Patients at Risk for Myocardial Injury. Circulation. 96(8). 2641–2648. 309 indexed citations
17.
Gelber, Richard D., Stephen E. Sallan, Harvey J. Cohen, et al.. (1993). Central nervous system treatment in childhood acute lymphoblastic leukemia. Long-term follow-up of patients diagnosed between 1973 and 1985. Cancer. 72(1). 261–270. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yvan Samson Breakdown of academic impact, for papers by Donna E. Levy Breakdown of academic impact, for papers by Elly Barry Breakdown of academic impact, for papers by Kasey J. Leger Breakdown of academic impact, for papers by Jos P.M. Bökkerink Breakdown of academic impact, for papers by Lucius F. Sinks Breakdown of academic impact, for papers by Demetrius Traggis Breakdown of academic impact, for papers by Claudine Schmitt Breakdown of academic impact, for papers by Dipti Gupta Breakdown of academic impact, for papers by Furqan Shaikh
Rankless by CCL
2026